APA (7th ed.) Citation

Han, X., Lobo, F., Broder, M. S., Chang, E., Gibbs, S. N., Ridley, D. J., & Yermilov, I. Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors. Columbia Data Analytics, LLC.

Chicago Style (17th ed.) Citation

Han, Xue, Francis Lobo, Michael S. Broder, Eunice Chang, Sarah N. Gibbs, David J. Ridley, and Irina Yermilov. Persistence with Early-Line Abatacept Versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors. Columbia Data Analytics, LLC.

MLA (9th ed.) Citation

Han, Xue, et al. Persistence with Early-Line Abatacept Versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors. Columbia Data Analytics, LLC.